Date: 2013-01-31
Type of information: Grant
Company: BIOSID consortium (Ceed (France), Defymed (France), AvantiCell (UK), the Department of Endocrinology, Diabetes and Nutrition from the Montpellier UHC(France), the Nuffield department of Surgical Sciences of the Oxford University (UK),Endocells (France), the laboratory of Experimental Surgery of the Catholic University of Louvain (UCL) (Belgium)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: € 5.5 million
Funding type: grant
Planned used: The grant will be used to support a first clinical validation of the bioartificial pancreas MAILPAN®, which prototype has been developed through two previous European projects, led by CeeD.
Others: * On January 30, 2013, the Centre européen d\'étude du Diabète (CeeD) and its partners have just received nearly € 5.5 million for the co-funding of the european BIOSID project. This project is coordinated by the CeeD and includes 7 partners from 3 different countries [Defymed (France), AvantiCell (UK), the Department of Endocrinology, Diabetes and Nutrition from the Montpellier UHC(France), the Nuffield department of Surgical Sciences of the Oxford University (UK),Endocells (France), the laboratory of Experimental Surgery of the Catholic University of Louvain (UCL) (Belgium)].The project aims to understand the needs of insulin-secreting cells in the bioartificial pancreas, to meet these needs in order to improve their life expectancy in the bioartificial pancreas and to validate the bioartificial pancreas, associated with insulin-secreting cells, in large animals and then in humans.
The full consortium brings together 4 SMEs and 3 public research organizations, from three different countries (France, Belgium and United Kingdom), which will each have a role in the validation of the various stages of the project. The consortium’s expertise includes encapsulation techniques, cellular, transplantation and formulation engineering as well as a clinical expertise.
Therapeutic area: Metabolic diseases
